Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Trading Arrangement: Trading Arrangement [Axis] Maximum Maximum [Member] Title of 12(b) Security Title of 12(b) Security Subsequent Event Subsequent Event [Member] Net (loss) income attributable to Amneal Pharmaceuticals, Inc. Net Income (Loss) Available to Common Stockholders, Diluted Contract Charge - Backs and Sales Volume Allowances Contract Chargebacks And Sales Volume Allowances [Member] Contract Charge-backs And Sales Volume Allowances [Member] Adjustment to Compensation, Amount Adjustment to Compensation Amount Segment Reporting [Abstract] Segment Reporting [Abstract] Schedule of Finite-Lived Intangible Assets, Future Amortization Expense Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense [Table Text Block] Accrued compensation Employee-related Liabilities, Current Accrued Medicaid and commercial rebates Accrued Sales Rebates Current Accrued sales rebates current. Leases Lessee, Finance Leases [Text Block] Entity Common Stock, Shares Outstanding (in shares) Entity Common Stock, Shares Outstanding Alkermes Plc Alkermes Plc [Member] Alkermes Plc Property, plant and equipment Business Combination, Recognized Asset Acquired, Property, Plant, and Equipment Working capital adjustments Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Working Capital Adjustments Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Working Capital Adjustments Collaborative arrangement license revenue agreement Collaborative Arrangement License Revenue Agreement Collaborative Arrangement License Revenue Agreement Civil Prescription Opioids Settlement Agreement Civil Prescription Opioids Settlement Agreement [Member] Civil Prescription Opioids Settlement Agreement Leases [Abstract] Other comprehensive (loss) income: Other Comprehensive Income (Loss), Net of Tax [Abstract] Intangible Asset, Finite-Lived, Acquired [Line Items] Intangible Asset, Finite-Lived, Acquired [Line Items] Related Party Transactions Related Party Transactions Disclosure [Text Block] Acquisition of non-controlling interest Cash consideration Payments to Noncontrolling Interests Common stock, par value (in usd per share) Common Stock, Par or Stated Value Per Share Intangible assets, net Intangible assets, net Intangible Asset, Excluding Goodwill, after Accumulated Amortization Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Research and development Research and Development [Member] Research and Development Number of reportable segments Number of Reportable Segments Total current liabilities Liabilities, Current Work in process Inventory, Work in Process, Net of Reserves Concentration Risk [Table] Concentration Risk [Table] Cash flow hedge loss to be reclassified within 12 months Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months Entity Address, City or Town Entity Address, City or Town Customer D Customer D [Member] Customer D Receivables [Abstract] Receivables [Abstract] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Distribution Distribution Service [Member] Royalties Royalties [Member] Royalties Royalty expense Royalty Expense Net Intangible Asset, Finite-Lived, after Accumulated Amortization Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Antitrust class action litigation Antitrust Class Action Litigation [Member] Antitrust Class Action Litigation Schedule of Major Categories of Sales-Related Deductions Summary of Valuation Allowance [Table Text Block] Significant Other Observable Inputs (Level 2) Level 2 Fair Value, Inputs, Level 2 [Member] Other (expense) income: Nonoperating Income (Expense) [Abstract] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Operating lease liabilities Business Combination, Recognized Liability Assumed, Operating Lease, Liability, Noncurrent Business Combination, Recognized Liability Assumed, Operating Lease, Liability, Noncurrent Name of Property [Axis] Name of Property [Axis] Product development and studies Product Development and Studies Expense Product Development and Studies Expense Subsequent Event Type Subsequent Event Type [Axis] Concentration Risk Type Concentration Risk Type [Axis] Unrealized gain (loss) on cash flow hedge, net of tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Schedule of Segment Reporting Segment Reporting [Table Text Block] Use of Estimates Use of Estimates, Policy [Policy Text Block] Related Party Related and Nonrelated Parties [Axis] Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Other comprehensive income (loss) attributable to Amneal Pharmaceuticals, Inc. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Schedule of Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Repayment of credit facility Repayments of Lines of Credit Schedule of Lessee, Operating Lease, Liability, to be Paid, Maturity Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] SEC Schedule, 12-09, Valuation Allowances and Reserves SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain] Document Period End Date Document Period End Date Debt incurred Debt Instrument, Face Amount 2028 Lessee, Operating Lease, Liability, to be Paid, Year Two Denominator: Earnings Per Share, Basic [Abstract] Long-term compensation Long-Term Compensation Liabilities Long-Term Compensation Liabilities Long-term debt, net Business Combination, Recognized Liability Assumed, Long-Term Debt, Noncurrent Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Common Class B Common Class B [Member] Entity Shell Company Entity Shell Company Consolidation Items Consolidation Items [Domain] Change in fair value during period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Current portion of operating lease liabilities Operating Lease, Liability, Current Accrued Medicaid and Commercial Rebates Accrued Medicaid And Commercial Rebates [Member] Accrued Medicaid And Commercial Rebates [Member] (Loss) Earnings per Share Earnings Per Share [Text Block] Net (loss) income per share attributable to Amneal Pharmaceuticals, Inc.’s Class A common stockholders: Earnings Per Share [Abstract] Document Fiscal Period Focus Document Fiscal Period Focus Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Trading Symbol Trading Symbol Discount rate Measurement Input, Discount Rate [Member] Purchases of property, plant and equipment Payments to Acquire Property, Plant, and Equipment Schedule of Preliminary Purchase Price Allocation for the Acquisitions Business Combination, Recognized Asset Acquired and Liability Assumed [Table Text Block] Company Selected Measure Name Company Selected Measure Name Selling, general and administrative Selling, General and Administrative - Operating Lease [Member] Selling, General and Administrative - Operating Lease Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Business Combination, Contingent Consideration, Type [Axis] Business Combination, Contingent Consideration, Type [Axis] Concentration Risk [Line Items] Concentration Risk [Line Items] Estimated closing cash Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Payments to Acquire Businesses, Gross Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Payments to Acquire Businesses, Gross Credit Facility Credit Facility [Domain] Cash flows from operating activities: Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Current portion of operating lease liabilities Business Combination, Recognized Liability Assumed, Operating Lease, Liability, Current Business Combination, Recognized Liability Assumed, Operating Lease, Liability, Current Other current receivables Other Receivables, Net, Current Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Other Comprehensive Income, Other, Net of Tax Other Comprehensive Income, Other, Net of Tax Development and commercialization agreement - Filgrastim and Pegfilgrastim - Royalty expense (Releuko and Fylnetra) Cost Of Goods Sold Development And Commercialization Agreement - Filgrastim And Pegfilgrastim - Royalty Expense (Releuko And Fylnetra) [Member] Cost Of Goods Sold Development And Commercialization Agreement - Filgrastim And Pegfilgrastim - Royalty Expense (Releuko And Fylnetra) Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Payments for tax receivable agreement Income Tax, Payments for Tax Receivable Agreement Income Tax, Payments for Tax Receivable Agreement Term Loan Due 2032 Term Loan Due 2032 [Member] Term Loan Due 2032 Gross profit Gross Profit Business Combination, Intangible Asset, Acquired, Finite-Lived [Table] Business Combination, Intangible Asset, Acquired, Finite-Lived [Table] License agreement License Agreement [Member] License Agreement Cash conversion payments Litigation Settlement, To Be Paid, Cash Conversion Payments Litigation Settlement, To Be Paid, Cash Conversion Payments Award Timing Predetermined Award Timing Predetermined [Flag] Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Quoted Prices in Active Markets (Level 1) Fair Value, Inputs, Level 1 [Member] Schedules of Percent of Gross Trade Receivables Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Interest rate swap Derivative Asset, Noncurrent Effective tax rate Effective Income Tax Rate Reconciliation, Percent Avtar Investments LLC - consulting services Avtar Investments, LLC [Member] Avtar Investments, LLC Effect of dilutive securities (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Non-cash property losses Noncash Property Losses Noncash Property Losses Preferred stock, par value (in usd per share) Preferred Stock, Par or Stated Value Per Share Long-term debt fair value Long-Term Debt, Fair Value Depreciation Depreciation Other Long-Term Liabilities Other Liabilities Disclosure [Text Block] Scenario [Domain] Scenario [Domain] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Concentration Risk Type Concentration Risk Type [Domain] Operating lease right-of-use assets Business Combination, Recognized Asset Acquired, Operating Lease, Right-Of-Use Asset Business Combination, Recognized Asset Acquired, Operating Lease, Right-Of-Use Asset AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward] Imputed interest rate Litigation Settlement, Imputed Interest Rate Litigation Settlement, Imputed Interest Rate Preliminary fair value of consideration transferred Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Debt Instrument, Name Debt Instrument, Name [Domain] Outstanding line of credit facility Long-Term Line of Credit Security deposits Deposits Assets, Noncurrent Expiration Date Trading Arrangement Expiration Date Number of cases filed in MDL and other federal courts Loss Contingency, Number of Cases in Federal Courts Loss Contingency, Number of Cases in Federal Courts Long-term deposits and prepaid expenses Long-term Deposits and Prepaid Expenses, Noncurrent Long-term Deposits and Prepaid Expenses, Noncurrent Total stockholders’ equity (deficiency) Stockholders' equity beginning balance Stockholders' equity ending balance Accumulated other comprehensive gain (loss) Equity, Including Portion Attributable to Noncontrolling Interest Buildings Building [Member] Nonrelated Party Nonrelated Party [Member] Affiliated Entity Affiliated Entity [Member] Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Derivative [Table] Derivative [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Related party receivables Business Combination, Recognized Asset Acquired, Receivable, Current Cash flows from investing activities: Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Related Party Transaction Related Party Transaction [Axis] Term Loan Term Loan [Member] Term Loan Net income (loss) Business Combination, Pro Forma Information, Pro Forma Income (Loss), after Tax Other dosage forms Other Dosage Forms [Member] Other Dosage Forms Segments Segments [Domain] Debt Debt Disclosure [Text Block] Scenario [Axis] Scenario [Axis] Less: debt issuance costs Debt Issuance Costs, Net Business Combination [Table] Business Combination [Table] Water Damage at India Facility Water Damage at India Facility [Member] Water Damage at India Facility PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Institutional Institutional [Member] Institutional. Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract] AvKARE, LLC and R&S AvKARE, LLC and R&S [Member] AvKARE, LLC and R&S Total Amneal Pharmaceuticals, Inc. stockholders’ equity (deficiency) Equity, Attributable to Parent Other assets Business Combination, Recognized Asset Acquired, Other Asset, Noncurrent Equal distributions, amount Payments For Legal Settlements, Annual Distributions, Amount Payments For Legal Settlements, Annual Distributions, Amount AzaTech Pharma LLC AzaTech Pharma LLC - Supply Agreement [Member] AzaTech Pharma LLC - Supply Agreement Thereafter Lessee, Operating Lease, Liability, to be Paid, after Year Four Lessee, Operating Lease, Liability, to be Paid, after Year Four Assets Assets Assets [Abstract] Product rights Contractual Rights [Member] Consideration paid in common stock (in shares) Business Combination, Consideration Transferred, Equity Interest, Share Issued, Number of Shares Insider Trading Policies and Procedures [Line Items] Accounts Payable and Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Allowance for credit losses Accounts Receivable, Allowance for Credit Loss, Current Performance stock units Performance Shares [Member] Prepaid expenses and other current assets Total prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Prepaid Expenses and Other Current Assets Supplemental Balance Sheet Disclosures [Text Block] Interest expense, net Interest Income (Expense), Nonoperating Litigation settlement, percentage of product value Litigation Settlement, Percentage Of Product Value Litigation Settlement, Percentage Of Product Value Selling, general and administrative Selling, General and Administrative - Warehousing, Logistics, and Distribution Services [Member] Selling, General and Administrative - Warehousing, Logistics, and Distribution Services Liability for legal matters Estimated Litigation Liability Potentially dilutive securities excluded from earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Schedule of Changes in Goodwill by Segment Goodwill [Table Text Block] Entity Central Index Key Entity Central Index Key Carickhoff v. Amneal Pharmaceuticals Inc., et al. Carickhoff v. Amneal Pharmaceuticals Inc. [Member] Litiagation Case Less: Accumulated depreciation Property, Plant, and Equipment, Accumulated Depreciation, Depletion, and Amortization Contract charge-backs and sales volume allowances Contract Charge Backs And Sales Volume Allowances Current Contract Charge-Backs And Sales Volume Allowances, Current Equity [Abstract] Equity [Abstract] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Payments for legal settlements Payments for Legal Settlements Other, net of tax Stockholders' Equity, Other Other comprehensive (loss) gain before reclassification Other Comprehensive Income (Loss), before Reclassifications, Net of Tax Ownership Ownership [Axis] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Number of facilities damaged Number of Damaged Facilities Number of Damaged Facilities Designated as Hedging Instrument Designated as Hedging Instrument [Member] Financing lease liabilities Finance Lease, Liability, Noncurrent Affordable Medicines Affordable Medicines Segment [Member] Affordable Medicines Segment Kashiv R&D expenses Business Combination Research and Development Expense Business Combination Research and Development Expense Kashiv Acquisition Kashiv Acquisition [Member] Kashiv Acquisition Number of cases Loss Contingency, Number Of Cases Settled Loss Contingency, Number Of Cases Settled Basis spread on variable rate (as a percent) Debt Instrument, Basis Spread on Variable Rate Variable Rate [Domain] Variable Rate [Domain] Total settlement payments Litigation Settlement, To Be Paid, Gross Litigation Settlement, To Be Paid, Gross Accumulated Other Comprehensive Loss Accumulated other comprehensive loss AOCI Attributable to Parent [Member] All Individuals All Individuals [Member] Schedule of Liabilities Related to Legal Matters Schedule of Loss Contingencies by Contingency [Table Text Block] Balance, beginning of period Balance, end of period SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount Finished goods Inventory, Finished Goods, Net of Reserves Contingent consideration - related party - long term Contingent consideration long term Business Combination, Contingent Consideration, Liability, Noncurrent Commercial operations and salesforce Commercial Operations And Salesforce Expense Commercial Operations And Salesforce Expense Equity consideration Business Combination, Consideration Transferred, Equity Interest Lease agreement Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract Statement [Line Items] Statement [Line Items] Schedule of Tax Receivable Agreement Schedule of Tax Receivable Agreement [Table Text Block] Schedule of Tax Receivable Agreement Total assets Assets Operating Leases Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity [Abstract] Kanan, LLC - operating lease Kanan L L C [Member] Kanan, LLC [Member] Operating Segments Operating Segments [Member] Discount for lack of marketability Shares Issued, Price Per Share, Discount, Percentage Shares Issued, Price Per Share, Discount, Percentage Total liabilities assumed Business Combination, Recognized Liability Assumed, Liability Income and other tax receivables Income And Other Taxes Receivable Income and other taxes receivable. PEO PEO [Member] Related party payables - long term Total other long-term liabilities Related party payables - long term Other Liabilities, Noncurrent Goodwill Beginning, balance of period Ending, balance of period Goodwill Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Payments of principal on debt, revolving credit facilities and financing leases Repayments Of Long Term Debt, Revolving Credit Facility And Financing Lease Obligations Repayments of long term debt and financing lease obligations. Corporate Headquarters Corporate Headquarters [Member] Corporate Headquarters Stockholders’ Accumulated Deficit Retained Earnings [Member] Operating lease liabilities Operating Lease, Liability, Noncurrent Depreciation and amortization Depreciation Depletion And Amortization Excluding Amortization Of Debt Issuance Costs Depreciation, Depletion And Amortization, Excluding Amortization Of Debt Issuance Costs Revolving Credit Facility Revolving Credit Facility [Member] Auto-Injector Ephinephrine Auto-Injector [Member] Ephinephrine Auto-Injector Shares beginning balance (in shares) Shares ending balance (in shares) Common Stock, Shares, Outstanding Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Award Timing Disclosures [Line Items] Foreign currency translation adjustments Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Diluted (in dollars per share) Diluted (in dollars per share) Earnings Per Share, Diluted License supply agreement, potential future milestone payments Collaborative Agreement, Milestone Payments Collaborative Agreement, Milestone Payments Prepaid expenses, other current assets and other assets Increase (Decrease) in Prepaid Expense and Other Assets Regulatory fees Regulatory Fees Expense Regulatory Fees Expense Litigation Case Litigation Case [Domain] Litigation settlement, product supply price (in USD per twin pack) Litigation Settlement, Product Supply Price Litigation Settlement, Product Supply Price Amortization of intangible assets Intangible Asset, Finite-Lived, Amortization Expense Apace Packaging, LLC - packaging agreement Apace Packaging, LLC Packaging Agreement [Member] Apace Packaging, LLC Packaging Agreement Intangible Asset, Finite-Lived [Line Items] Intangible Asset, Finite-Lived [Line Items] Ownership Ownership [Domain] Oral liquid Oral Liquid [Member] Oral Liquid Net revenue Revenue from Contract with Customer, Excluding Assessed Tax Pfizer Arrangement Pfizer Arrangement [Member] Pfizer Arrangement Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Intangible assets, cost Intangible Asset, Excluding Goodwill, before Accumulated Amortization Loan for land purchase - related party Notes Issued 2030 Litigation Settlement, To Be Paid, Year Four Litigation Settlement, To Be Paid, Year Four Construction-in-progress Construction in Progress [Member] Storage agreement Storage Agreement, Research And Development [Member] Storage Agreement, Research And Development Class A common stock issued in connection with the Kashiv Acquisition Stock Issued Escrow deposit Escrow Deposit Operating income Operating Income (Loss) Generic Digoxin and Doxycycline Antitrust Litigation Generic Digoxin And Doxycycline Antitrust Litigation [Member] Generic Digoxin and Doxycycline Antitrust Litigation. Proceeds from issuance of debt Proceeds from Issuance of Debt Related Party Transaction Related Party Transaction [Domain] Acquisition Business Combination [Text Block] Vehicles Vehicles [Member] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Materials and supplies Supplies Expense Customer C Customer C Customer C [Member] Customer C [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Common stock, shares issued (in shares) Common Stock, Shares, Issued Other Assets Other Assets Disclosure [Text Block] Hormonal / allergy Hormonal Allergy [Member] Hormonal allergy. 2032 to 2034 Litigation Settlement, To Be Paid, After Year Five Litigation Settlement, To Be Paid, After Year Five Deferred revolving credit facility costs Deferred Costs, Noncurrent Trade accounts receivable, net Increase (Decrease) in Accounts Receivable Product and Service [Domain] Product and Service [Domain] Class of Stock [Line Items] Class of Stock [Line Items] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Operating loss Business Combination, Acquiree's Earnings (Loss) since Acquisition Date, Actual Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Product marketing Marketing and Advertising Expense 2029 Lessee, Operating Lease, Liability, to be Paid, Year Three Termination Date Trading Arrangement Termination Date (Increase) decrease in tax receivable agreement liability Increase (decrease) in tax receivable agreement liability (Increase) Decrease in Tax Receivable Agreement Liability (Increase) Decrease in Tax Receivable Agreement Liability Inventory Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Inventory Subsequent Events [Abstract] Subsequent Events [Abstract] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Marketed product rights Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Finite-Lived Contingent consideration for acquisition - related party Liabilities Assumed Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Central nervous system Central Nervous System [Member] Central nervous system. Fair Value as of Grant Date Award Grant Date Fair Value Schedule of Goodwill [Table] Goodwill [Table] Increase (Decrease) in Temporary Equity [Roll Forward] Increase (Decrease) in Temporary Equity [Roll Forward] Accrued returns allowance Accrued Sales Returns Allowance Current Accrued sales returns allowance current. Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Other Liabilities [Line Items] Other Liabilities [Line Items] Other liabilities. Arrangement Duration Trading Arrangement Duration Consolidation Items Consolidation Items [Axis] Specialty Amneal Specialty Pharma Segment [Member] Amneal Specialty Pharma Segment [Member] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Registrant Name Entity Registrant Name Litigation Settlement, Option [Axis] Litigation Settlement, Option [Axis] Litigation Settlement, Option Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Schedule of the Company’s Indebtedness at Fair Value Fair Value Disclosure of Asset and Liability Not Measured at Fair Value [Table Text Block] Cost Intangible Asset, Finite-Lived, before Accumulated Amortization Alvotech hf. License Agreement Alvotech hf. License Agreement [Member] Alvotech hf. License Agreement Tracy Properties LLC Ellodi Pharmaceuticals, L.P. [Member] Ellodi Pharmaceuticals, L.P. Other Assets [Abstract] Other Assets [Abstract] Accounts payable, accrued expenses and other liabilities Increase (Decrease) in Accounts Payable and Accrued Liabilities Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Receivable from sellers related to purchase price adjustment Business Combination, Consideration Transferred, Receivable From Sellers Related To Purchase Price Adjustment Business Combination, Consideration Transferred, Receivable From Sellers Related To Purchase Price Adjustment Goodwill [Roll Forward] Goodwill [Roll Forward] Furniture and fixtures Furniture and Fixtures [Member] Intangible Asset, Finite-Lived, Class Intangible Asset, Finite-Lived, Class [Domain] Intangible Asset, Finite-Lived, Class [Domain] Proceeds from financing obligations Proceeds From Financing Obligations Proceeds From Financing Obligations Other intangible assets Trade Names [Member] Schedule of Assets and Liabilities Measured at Fair Value on a Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Award Type Award Type [Domain] Remainder of 2026 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Fair Value Measurements Fair Value Disclosures [Text Block] Significant Unobservable Inputs (Level 3) Fair Value, Inputs, Level 3 [Member] Income tax, liabilities under tax receivable agreement unrecorded Income Tax, Unrecorded Tax Receivable Agreement Liability Income Tax, Unrecorded Tax Receivable Agreement Liability 2027 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year One Ownership percentage by noncontrolling owners (percent) Subsidiary, Ownership Percentage, Noncontrolling Owner Schedule of Property Losses and Associated Expenses Schedule of Unusual or Infrequent Items, or Both [Table Text Block] Total assets acquired Business Combination, Recognized Asset Acquired, Asset Including Goodwill Business Combination, Recognized Asset Acquired, Asset Including Goodwill Legal Entity Legal Entity [Axis] Credits/payments issued during the period SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction Schedule of Company’s Alliance and Collaboration Agreements Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block] Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Cash, cash equivalents, and restricted cash - beginning of period Cash, cash equivalents, and restricted cash - end of period Cash, cash equivalents, and restricted cash - end of period Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Schedule of Finite-Lived Intangible Assets [Table] Intangible Asset, Finite-Lived [Table] Accrued professional fees Accrued Professional Fees, Current Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] In-process research and development (“IPR&D”) Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Indefinite-Lived Non-NEOs Non-NEOs [Member] Cash consideration Payments to Acquire Businesses, Gross 2028 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Two Members - tax receivable agreement Members - Tax Receivable Agreement [Member] Members - Tax Receivable Agreement Customer Customer [Domain] Schedule of Components of Inventories Schedule of Inventory, Current [Table Text Block] Leases Lessee, Operating Leases [Text Block] Long-term Debt, Type Long-Term Debt, Type [Domain] Statistical Measurement Statistical Measurement [Axis] Award Type Award Type [Axis] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Stockholders’ accumulated deficit Retained Earnings (Accumulated Deficit) Product and Service [Axis] Product and Service [Axis] Eligibility period Business Combination, Contingent Consideration, Liability, Period Business Combination, Contingent Consideration, Liability, Period Long-term restricted cash Restricted Cash, Noncurrent 2028 Litigation Settlement, To Be Paid, Year Two Litigation Settlement, To Be Paid, Year Two Tax on reclassification of cash flow hedge to earnings Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Change in fair value of contingent consideration Change in fair value of contingent consideration Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease) Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Common Stock Common Stock [Member] Litigation Settlement, Option One Litigation Settlement, Option One [Member] Litigation Settlement, Option One Litigation settlement, charges Litigation Settlement, Fee Expense Ranitidine Litigation Ranitidine Litigation [Member] Ranitidine Litigation Concentration Risk Benchmark Concentration Risk Benchmark [Axis] Currency translation Goodwill, Foreign Currency Translation, Gain (Loss) Impairment of inventory Impairment of Inventory [Member] Impairment of Inventory Development and commercialization agreement - Pegfilgrastim Auto Injector - milestone Research and development Development and commercialization agreement - Pegfilgrastim Auto Injector - milestone [Member] Research and development Development and commercialization agreement - Pegfilgrastim Auto Injector - milestone Total liabilities and stockholders’ equity (deficiency) Liabilities and Equity Stock options Share-Based Payment Arrangement, Option [Member] Non-controlling interests Equity, Attributable to Noncontrolling Interest Segments Segments [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Related Party Related and Nonrelated Parties [Domain] Restructuring and other charges Restructuring Charges Tabular List, Table Tabular List [Table Text Block] Long-term restricted cash included in other assets - end of period Restricted Cash and Cash Equivalent, Noncurrent Additional paid-in capital Additional Paid in Capital Acquisition of intangible assets Payments to Acquire Intangible Assets Kashiv Specialty Pharmaceuticals, LLC Kashiv Specialty Pharmaceuticals, LLC [Member] Kashiv Specialty Pharmaceuticals, LLC 2029 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Three Remainder of 2026 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Remainder of Fiscal Year Other operating income Other operating income Other Operating Income (Expense), Net Name Awards Close in Time to MNPI Disclosures, Individual Name Civil prescription opioid litigation Civil Prescription Opioid Litigation [Member] Civil Prescription Opioid Litigation Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Property, Plant and Equipment, Type Long-Lived Asset, Class [Domain] Business Combination, Contingent Consideration, Type [Domain] Business Combination, Contingent Consideration, Type [Domain] mAbxience S.L. mAbxience S.L. Agreement [Member] mAbxience S.L. Agreement Property, Plant, and Equipment [Table] Property, Plant, and Equipment [Table] Preferred stock, $0.01 par value, 2,000 shares authorized at both September 30, 2026 and December 31, 2025; none issued at both September 30, 2026 and December 31, 2025 Preferred Stock, Value, Issued Adjustment to Compensation: Adjustment to Compensation [Axis] Reclassification of cash flow hedge to earnings, net of tax of $0 Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax Tax and other distributions to non-controlling interests Tax And Other Distribution To Noncontrolling Interest Financing Activities Tax And Other Distribution To Non-controlling Interest, Financing Activities Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Prepaid taxes Prepaid Taxes Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activity Hedging Designation Hedging Designation [Axis] Credit Facility Credit Facility [Axis] Number of cases filed in state courts Loss Contingency, Number of Cases in State Courts Loss Contingency, Number of Cases in State Courts Name Measure Name Pay vs Performance Disclosure [Line Items] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Debt Instrument [Line Items] Debt Instrument [Line Items] Incremental Term Loan Incremental Term Loan [Member] Incremental Term Loan Prepaid regulatory fees Prepaid Regulatory Fees Current Prepaid Regulatory Fees, Current Additional Paid-in Capital Additional Paid-in Capital [Member] Intangible Asset, Indefinite-Lived, Class [Axis] Intangible Asset, Indefinite-Lived, Class [Axis] Name Trading Arrangement, Individual Name Cash and cash equivalents Cash and cash equivalents - end of period Cash and Cash Equivalent Raw materials Inventory, Raw Materials, Net of Reserves Company Selected Measure Amount Company Selected Measure Amount Tranche Two Regulatory Milestones, Tranche Two [Member] Regulatory Milestones, Tranche Two SOFR Secured Overnight Financing Rate (SOFR) [Member] Liability to be settled with products Estimated Litigation Liability, to be Settled with Product Estimated Litigation Liability, to be Settled with Product Specialty Specialty Segment [Member] Specialty Segment [Member] Shares issued upon vesting of stock-based compensation awards (in shares) Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture Transdermal Transdermal [Member] Transdermal Weighted average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Aggregate cash conversion payments Litigation Settlement, To Be Paid, Cumulative Cash Conversion Payments Litigation Settlement, To Be Paid, Cumulative Cash Conversion Payments Non-PEO NEO Non-PEO NEO [Member] Tax and other distributions, net Temporary Equity, Tax Distribution Temporary Equity, Tax Distribution Foreign exchange (loss) gain, net Gain (Loss), Foreign Currency Transaction, before Tax 2031 Litigation Settlement, To Be Paid, Year Five Litigation Settlement, To Be Paid, Year Five Effect of dilutive securities: Dilutive Securities, Effect on Basic Earnings Per Share [Abstract] Customer Concentration Risk Customer Concentration Risk [Member] Net income (loss) Net Income (Loss), Including Portion Attributable to Nonredeemable Noncontrolling Interest Cost of goods sold Cost of Product and Service Sold SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward] Award Timing Method Award Timing Method [Text Block] Other Product and Service, Other [Member] Net decrease in cash, cash equivalents, and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Other Other Research and Development Expense Less: imputed interest at a rate of 5.5% Litigation Settlement, Imputed Interest At Weighted-Average Rate Litigation Settlement, Imputed Interest At Weighted-Average Rate Forecast Forecast [Member] Reclassification of cash flow hedge Interest Rate Cash Flow Hedge Gain (Loss) Reclassified to Earnings, Net Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Litigation settlement agreement terms Litigation Settlement, Payment Terms Litigation Settlement, Payment Terms Net (loss) income attributable to Amneal Pharmaceuticals, Inc. Net (loss) income attributable to Amneal Pharmaceuticals, Inc. before accretion of redeemable non-controlling interests Net Income (Loss) Attributable to Parent Long-term Debt, Type Long-Term Debt, Type [Axis] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Orion Corporation Orion Corporation [Member] Orion Corporation Balance Sheet Location Location, Statement of Financial Position, Balance [Axis] Proceeds from sale of property, plant and equipment Proceeds from Sale of Property, Plant, and Equipment Restatement Determination Date: Restatement Determination Date [Axis] Schedule of Changes in Accumulated Other Comprehensive Loss by Component Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Litigation settlement amount Litigation Settlement, Amount Awarded to Other Party Loss contingency, new claims filed, number Loss Contingency, New Claims Filed, Number Cash discount allowances Cash Discount Allowances Current Cash Discount Allowances, Current Schedule of Prepaid Expenses and Other Current Assets Schedule of Other Assets [Table Text Block] Property, plant, and equipment Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Property, Plant, and Equipment Total Income Tax, Liabilities Under Tax Receivable Agreement Income Tax, Liabilities Under Tax Receivable Agreement Unusual or Infrequent Item, or Both [Line Items] Unusual or Infrequent Item, or Both [Line Items] Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Tax receivable agreement liability - long term Income Tax, Liabilities Under Tax Receivable Agreement, Noncurrent Income Tax, Liabilities Under Tax Receivable Agreement, Noncurrent Schedule of Other Assets Schedule of Other Assets, Noncurrent [Table Text Block] Statistical Measurement Statistical Measurement [Domain] Unusual or Infrequent Items, or Both [Abstract] Document Fiscal Year Focus Document Fiscal Year Focus Acquisition related cost, expense Business Combination, Acquisition-Related Cost, Expense Customer Customer [Axis] Common stock Common Stock, Value, Issued 2027 Lessee, Operating Lease, Liability, to be Paid, Year One Accretion of redeemable non-controlling interests Adjustments to Additional Paid in Capital, Increase in Carrying Amount of Redeemable Preferred Stock Employee payroll tax withholding on restricted stock unit and performance stock unit vesting Payment, Tax Withholding, Share-Based Payment Arrangement Schedule of Long-Term Debt Schedule of Long-Term Debt Instruments [Table Text Block] Other long-term assets Other Assets, Miscellaneous, Noncurrent Other prepaid assets Other Prepaid Expense, Current Line of Credit Line of Credit [Member] Restatement Determination Date Restatement Determination Date Inventory provision Inventory Write-down Property Losses and Associated Expenses Unusual or Infrequent Items, or Both, Disclosure [Text Block] Cost of goods sold Cost of Goods Sold [Member] Cost of Goods Sold Projected year of payment, payments discounted, percentage Measurement Input, Projected Year of Payment, Payments Discounted, Percentage [Member] Measurement Input, Projected Year of Payment, Payments Discounted, Percentage Amendment Flag Amendment Flag Goodwill [Line Items] Goodwill [Line Items] Current liabilities: Liabilities, Current [Abstract] Probability of payment Measurement Input, Payment Probability [Member] Measurement Input, Payment Probability Loss Contingencies [Table] Loss Contingencies [Table] Land purchase from family members of the Co-Chief Executive Officers Co-Chief Executive Officers [Member] Co-Chief Executive Officers Total long-term liabilities Liabilities, Noncurrent Shares issued in connection with the acquisition of Kashiv Stock Issued During Period, Value, Acquisitions Sellers Of Kashiv Sellers Of Kashiv [Member] Sellers Of Kashiv 2029 Litigation Settlement, To Be Paid, Year Three Litigation Settlement, To Be Paid, Year Three Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Regulatory Milestones Regulatory Milestones [Member] Regulatory Milestones Property, Plant, and Equipment [Abstract] Entity Address, State or Province Entity Address, State or Province PEO Total Compensation Amount PEO Total Compensation Amount Manufacturing And Warehouse Facility Manufacturing And Warehouse Facility [Member] Manufacturing And Warehouse Facility Basic (in shares) Weighted-average shares outstanding - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Deposits and advances Contract with Customer, Asset, after Allowance for Credit Loss, Current Schedule of Related Party Transactions Schedule of Related Party Transactions [Table Text Block] Loss Contingencies [Line Items] Loss Contingencies [Line Items] SEC Schedule, 12-09, Valuation Allowances and Reserves Type SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis] 2030 Lessee, Operating Lease, Liability, to be Paid, Year Four Collaborative arrangement term (in years) Collaborative Arrangement Term Collaborative Arrangement, Term SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table] Deposits for future acquisition of property, plant and equipment Payments to Acquire Property, Plant, and Equipment, Deposits Payments to Acquire Property, Plant, and Equipment, Deposits Chargebacks receivable Chargebacks Receivable, Current Chargebacks Receivable, Current Trade Accounts Receivable, Net Loans, Notes, Trade and Other Receivables Disclosure [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] United States Department of Justice Investigations United States Department of Justice Investigations [Member] United States Department of Justice Investigations Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Class of Stock Class of Stock [Axis] Net (loss) income attributable to Amneal Pharmaceuticals, Inc. Net Income (Loss) Available to Common Stockholders, Basic Revenue from Contract with Customer Benchmark Revenue from Contract with Customer Benchmark [Member] Accumulated Amortization Intangible Asset, Finite-Lived, Accumulated Amortization Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Current portion of long-term debt, net Less: current portion of long-term debt Long-Term Debt, Current Maturities Maximum potential future construction costs Collaborative Arrangement, Maximum Potential Future Construction Costs Collaborative Arrangement, Maximum Potential Future Construction Costs Tirzepatide Adalvo License and Supply Agreement Tirzepatide Adalvo License and Supply Agreement [Member] Tirzepatide Adalvo License and Supply Agreement Schedule of Cash Payments Schedule Of Cash Payments, Litigation Settlement, Maturity [Table Text Block] Schedule Of Cash Payments, Litigation Settlement, Maturity Intellectual property legal development expenses Intellectual Property Legal Development Expenses Intellectual Property Legal Development Expenses Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Litigation Case Litigation Case [Axis] MSN Laboratories Private Limited Supply and Distribution Agreement MSN Laboratories Private Limited Supply And Distribution Agreement [Member] MSN Laboratories Private Limited Supply And Distribution Agreement Land Land [Member] Non- Controlling Interests Noncontrolling Interest [Member] Tax on unrealized gain (loss) on cash flow hedge Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax Intangible assets Fair value of identifiable intangible assets acquired Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Excluding Goodwill Facilities costs Facilities Costs Facilities Costs Total debt, net of debt issuance costs Long-Term Debt Current portion of liabilities for legal matters Current portion of liabilities for legal matters Estimated Litigation Liability, Current Percentage of outstanding amount used to make quarter principal payments Debt Instrument, Quarterly Principal Payments, Percentage of Aggregate Outstanding Amount Debt Instrument, Quarterly Principal Payments, Percentage of Aggregate Outstanding Amount Property, Plant, and Equipment, Net Property, Plant, and Equipment [Text Block] Generic development supply agreement - recognition of deferred income Research And Development, Generic Development Supply Agreement - Recognition Of Deferred Income [Member] Research And Development, Generic Development Supply Agreement - Recognition Of Deferred Income Changes in assets and liabilities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Other Accumulated Gain (Loss), Other [Member] Accumulated Gain (Loss), Other Net cash used in investing activities Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Stockholders’ Equity (Deficiency) Equity [Text Block] Security Exchange Name Security Exchange Name Expected price of acquisition Business Combination, Price of Acquisition, Expected Net (loss) income per share attributable to Amneal Pharmaceuticals, Inc.’s Class A common stockholders: Earnings Per Share Basic And Diluted EPS [Abstract] Earnings Per Share Basic And Diluted EPS Injectable Injectable [Member] Injectable Customer A Customer A Customer A [Member] Customer A [Member] AzaTech Pharma LLC - supply agreement Aza Tech Pharma L L C [Member] AzaTech Pharma LLC. Schedule of Provision for Income Taxes Schedule of Provision for Income Taxes [Table Text Block] Schedule of Provision for Income Taxes Accrued interest Interest Payable, Current Schedule of Property, Plant and Equipment, Net Estimated Useful Lives Property, Plant, and Equipment [Table Text Block] Financing lease right-of-use assets Finance Lease, Right-of-Use Asset, after Accumulated Amortization Statement of Comprehensive Income [Abstract] R&S Solutions - equipment purchase R&S Solutions LLC [Member] R&S Solutions LLC Name Outstanding Recovery, Individual Name Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Other Liabilities [Table] Other Liabilities [Table] Other liabilities. IPR&D Indefinite-lived intangible assets (excluding goodwill) Intangible Asset, Excluding Goodwill, Indefinite-Lived Prepayment adjustments Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Prepayment Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Prepayment Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Charges (credit) related to legal matters, net Gain (Loss) from Litigation Settlement Litigation settlement discount on expected payments Litigation Settlement, Discount on Expected Payments Litigation Settlement, Discount on Expected Payments Amortization of debt issuance costs and discount Amortization of Debt Issuance Costs and Discounts Direct Customer Solutions, LLC Direct Customer Solutions, LLC [Member] Direct Customer Solutions, LLC Supplemental disclosure of non-cash investing and financing activity: Noncash Investing and Financing Items [Abstract] Total debt Incremental term loans Long-Term Debt, Gross Percentage of prescribed label (percent) Percentage of Prescribed Label Percentage of Prescribed Label Related Party Transactions [Abstract] Related Party Transactions [Abstract] Other long-term liabilities Other Sundry Liabilities, Noncurrent Collaborative arrangement upfront payment Collaborative Arrangement Upfront Payment Collaborative arrangement, up-front payment. Compensation Amount Outstanding Recovery Compensation Amount Individual: Individual [Axis] Voting interest acquired (percent) Business Combination, Voting Equity Interest Acquired, Percentage Diluted (in shares) Weighted-average shares outstanding - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Entity Emerging Growth Company Entity Emerging Growth Company Related Party Transaction [Line Items] Related Party Transaction [Line Items] Other Other Long-Term Debt [Member] Other Long-Term Debt Underlying Security Market Price Change Underlying Security Market Price Change, Percent Borrowings on revolving credit facilities Proceeds from Lines of Credit Settlement of pre-existing relationship Business Combination, Consideration Transferred, Settlement Of Pre Existing Relationship Business Combination, Consideration Transferred, Settlement Of Pre Existing Relationship Less: Imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Intangible Asset, Goodwill and Other [Abstract] Intangible Asset, Goodwill and Other [Abstract] Intangible Asset, Indefinite-Lived, Class [Domain] Intangible Asset, Indefinite-Lived, Class [Domain] Total lease payments Lessee, Operating Lease, Liability, to be Paid Customer B Customer B Customer B [Member] Customer B [Member] Accretion of redeemable non-controlling interests Accretion of Redeemable Noncontrolling Interest Accretion of Redeemable Noncontrolling Interest Total Litigation Settlement, Cash Settlement Litigation Settlement, Cash Settlement All Executive Categories All Executive Categories [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Orion Corporation License Agreement with Orion Corporation [Member] License Agreement with Orion Corporation Intangible Asset, Excluding Goodwill, Impairment Loss, Statement of Income or Comprehensive Income [Extensible Enumeration] Intangible Asset, Excluding Goodwill, Impairment Loss, Statement of Income or Comprehensive Income [Extensible Enumeration] Research and development equipment impairment charges Impairment charges Tangible Asset Impairment Charges Tracy Properties LLC - operating lease Tracy Properties L L C [Member] Tracy Properties LLC. Schedule of Basic and Diluted Earnings per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Segment Information Segment Reporting [Text Block] Minimum Minimum [Member] Accounts payable and accrued expenses Business Combination, Recognized Liability Assumed, Accounts Payable And Accrued Expense, Current Business Combination, Recognized Liability Assumed, Accounts Payable And Accrued Expense, Current Liabilities Liabilities [Abstract] Schedule of Disaggregated Revenue Disaggregation of Revenue [Table Text Block] Effect of foreign exchange rate on cash Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Weighted-average common shares outstanding: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Location, Statement of Income, Balance [Axis] Location, Statement of Income, Balance [Axis] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Fair value of contingent consideration – milestone payments Business Combination, Consideration Transferred, Liabilities Incurred Business Combination [Line Items] Business Combination [Line Items] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Debt instrument, interest rate floor (percent) Debt Instrument, Interest Rate Floor Debt Instrument, Interest Rate Floor Estimated useful life (in years) Weighted-Average Amortization Period (in years) Intangible Asset, Finite-Lived, Useful Life Accrued Returns Allowance Sales Returns and Allowances [Member] Exercise Price Award Exercise Price Development and commercialization agreement - Carfilzomib Research And Development - Development And Commercialization Agreement - Carfilzomib [Member] Research And Development - Development And Commercialization Agreement - Carfilzomib Segment Reporting [Line Items] Segment Reporting [Line Items] Document Quarterly Report Document Quarterly Report Twenty NEA, LLC Twenty NEA, LLC [Member] Twenty NEA, LLC Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Senior Notes Due 2032 Senior Notes Due 2032 [Member] Senior Notes Due 2032 Subtotal therapeutic classes Subtotal Therapeutic Classes [Member] Subtotal Therapeutic Classes Other therapeutic classes Other Therapeutic Classes [Member] Other therapeutic classes. Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Equity Component Equity Component [Domain] Measurement Input Type [Domain] Measurement Input Type [Domain] Subtotal Allowance For Accounts Receivable Current Allowance For Accounts Receivable, Current Gross accounts receivable Accounts Receivable, before Allowance for Credit Loss, Current Adoption Date Trading Arrangement Adoption Date Term Loan Facility Term Loan Facility [Member] Term Loan Facility Acquisition of non-controlling interests Noncontrolling Interest, Decrease from Purchase of Interests Noncontrolling Interest, Decrease from Purchase of Interests Counterparty Name Counterparty Name [Domain] Total other expense, net Nonoperating Income (Expense) Prepaid insurance Prepaid Insurance Title Trading Arrangement, Individual Title Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Other Liabilities Disclosure [Abstract] Accounting Policies [Abstract] Accounting Policies [Abstract] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Total Operating Lease, Liability Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Fair Value Interest Rate Cash Flow Hedge Asset at Fair Value Selling, general and administrative Total Selling, General and Administrative Expense Repayments of debt Repayments of Debt Collaborative arrangement, signing fee Collaborative Agreement, Signing Fee Collaborative Agreement, Signing Fee Business Combination Business Combination [Domain] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Change in fair value of contingent consideration Change In Fair Value Of Contingent Consideration [Member] Change In Fair Value Of Contingent Consideration Restricted stock units Restricted Stock Units (RSUs) [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Weighted Average Weighted Average [Member] Acquisition and integration costs Business Combination, Acquisition-Related And Integration-Related Costs, Expense Business Combination, Acquisition-Related And Integration-Related Costs, Expense All Adjustments to Compensation All Adjustments to Compensation [Member] Name of Property [Domain] Name of Property [Domain] Corporate and Other Segment Reporting, Reconciling Item, Corporate Nonsegment [Member] Business Combination Business Combination [Axis] Net cash provided by operating activities Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Accounts Receivable Accounts Receivable [Member] Number of cases filed Loss Contingency, Number Of Cases Loss Contingency, Number Of Cases Apace KY, LLC d/b/a Apace Packaging LLC - packaging agreement Apace K Y L L C [Member] Apace KY, LLC. Income Statement [Abstract] Income Statement [Abstract] Document Transition Report Document Transition Report Inventory purchases under development and commercialization agreement - Filgrastim and Pegfilgrastim (Releuko and Fylnetra) Inventory and Cost of Goods Sold Inventory Purchases Under Development And Commercialization Agreement Filgrastim And Pegfilgrastim (Releuko And Fylnetra) [Member] Inventory and Cost of Goods Sold Inventory Purchases Under Development And Commercialization Agreement Filgrastim And Pegfilgrastim (Releuko And Fylnetra) Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Decrease in interest rate Debt Instrument, Interest Rate, Increase (Decrease) Schedule of Intangible Assets Intangible Asset, Finite-Lived [Table Text Block] City Area Code City Area Code Deferred income from manufacturing services Deferred Income, Manufacturing Deferred Income, Manufacturing Kashiv Kashiv Biosciences, LLC Kashiv BioSciences, LLC [Member] Kashiv BioSciences LLC [Member] Generic development supply agreement - research and development material Research And Development, Generic Development Supply Agreement - Research And Development Material [Member] Research And Development, Generic Development Supply Agreement - Research And Development Material Subsequent Events Subsequent Events [Text Block] Volatility Measurement Input, Price Volatility [Member] Long-term restricted cash Business Combination, Recognized Asset Acquired, Restricted Cash, Noncurrent Business Combination, Recognized Asset Acquired, Restricted Cash, Noncurrent Name Forgone Recovery, Individual Name Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Entity Entity [Domain] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Accrued royalty income Accrued Royalties Receivable, Current Accrued Royalties Receivable, Current Current portion of operating lease liabilities Business Combination, Recognized Liability Assumed, Lease Obligation Statement of Other Comprehensive Income [Abstract] Statement of Other Comprehensive Income [Abstract] In-licensing and upfront milestones In Licensing And Upfront Milestones In Licensing And Upfront Milestones PharmaSophia, LLC - License and commercialization agreement - Risperidone - Royalty expense Pharma Sophia L L C [Member] PharmaSophia, LLC [Member] Inventories Business Combination, Recognized Asset Acquired, Inventory, Current Goodwill acquired during the period Goodwill, Acquired During Period Exercise of stock options (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Property, plant and equipment Property, Plant and Equipment, Net [Member] Property, Plant and Equipment, Net Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Subsequent Event Type Subsequent Event Type [Domain] Payables and Accruals [Abstract] Provision related to sales recorded in the period SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense Cash and cash equivalents Business Combination, Recognized Asset Acquired, Cash and Cash Equivalent Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Business Interruption Loss [Domain] Business Interruption Loss [Domain] Government label Government Label [Member] Government label. Schedule of Fair Value Measurement Inputs and Valuation Techniques Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Deferred income Deferred Income Entity Current Reporting Entity Current Reporting Status Net cash provided by (used in) financing activities Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Total Shareholder Return Amount Total Shareholder Return Amount Parking space lease Research And Development - Parking Space Lease [Member] Research And Development - Parking Space Lease Schedule of Preliminary Consideration Transferred Business Combination [Table Text Block] Pfizer Inc. (formerly Metsera, Inc.) License Agreement with Pfizer Inc [Member] License Agreement with Pfizer Inc Schedule of Pro Forma Information Business Combination, Pro Forma Information [Table Text Block] Research and development Total Research and Development Expense Adjustments to reconcile net income to net cash provided by operating activities: Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Loss Contingency Nature Loss Contingency Nature [Axis] Charges for property losses and associated expenses Total property losses and associated expenses Unusual or Infrequent Item, or Both, Loss, Gross Cash flows from financing activities: Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Property, plant and equipment, net Property, plant, and equipment, net Property, Plant, and Equipment, after Accumulated Depreciation, Depletion, and Amortization Revolving credit facility Line of Credit, Current Consideration paid in common stock (in usd per share) Shares Issued, Price Per Share Schedule of Revenue by Major Customers by Reporting Segments Segment Reporting, Entity-Wide Information Not Provided as Part of Reportable Segment, Customer, Extent of Reliance [Table Text Block] Derivative asset Derivative Asset Numerator: Net Income (Loss) Available to Common Stockholders, Basic [Abstract] Inventories Inventory Disclosure [Text Block] Intangible Asset, Finite-Lived, Class Intangible Asset, Finite-Lived, Class [Axis] Intangible Asset, Finite-Lived, Class [Axis] Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Goodwill and Other Intangible Assets Intangible Asset and Goodwill [Text Block] Underlying Securities Award Underlying Securities Amount Orion Corporation License Agreement with Orion Corporation Two [Member] License Agreement with Orion Corporation Two Revenue Recognition Revenue from Contract with Customer [Text Block] Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense [Abstract] Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense [Abstract] Financial Instruments Financial Instruments Disclosure [Text Block] Shares issued in connection with the acquisition of Kashiv (in shares) Stock Issued During Period, Shares, Acquisitions Inventories Increase (Decrease) in Inventories Weighted average discount rate (as a percent) Operating Lease, Weighted Average Discount Rate, Percent Segment Reporting [Table] Segment Reporting [Table] Repairs and maintenance and other expenses Repairs and Maintenance And Other Expenses [Member] Repairs and Maintenance And Other Expenses Net income (loss) Temporary Equity, Net Income Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Table] Computer equipment Computer Equipment [Member] Nationwide Opioids Settlement Agreement Nationwide Opioids Settlement Agreement [Member] Nationwide Opioids Settlement Agreement Number of states with cases Loss Contingency, Number of States Settling Claim With Free Products Loss Contingency, Number of States Settling Claim With Free Products Revenue Business Combination, Acquiree's Revenue since Acquisition Date, Actual Receivable Other Assets, Current Contingent consideration - related party - short term Business Combination, Contingent Consideration, Liability, Current Impairment of equipment Impairment of Equipment [Member] Impairment of Equipment Unusual or Infrequent Item, or Both [Table] Unusual or Infrequent Item, or Both [Table] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] All Trading Arrangements All Trading Arrangements [Member] Balance, December 31, 2025 Balance, September 30, 2026 Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Other Performance Measure, Amount Other Performance Measure, Amount Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Taxes on reclassification of cash flow hedge to earnings Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax Current Fiscal Year End Date Current Fiscal Year End Date Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Derivative [Line Items] Derivative [Line Items] Total future undiscounted lease payments under leases not yet commenced Unrecorded Unconditional Purchase Obligation Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Entity File Number Entity File Number Shares issued upon vesting of stock-based compensation awards Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Thereafter Intangible Asset, Finite-Lived, Estimated Amortization Expense, after Year Five Derivative gain (loss) reclassified from accumulated other comprehensive loss into income (loss) Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Measure: Measure [Axis] Net (loss) income attributable to Amneal Pharmaceuticals, Inc. before accretion of redeemable non-controlling interests Net Income (Loss) Attributable to Parent Before Accretion of Redeemable Noncontrolling Interest Net Income (Loss) Attributable to Parent Before Accretion of Redeemable Noncontrolling Interest Accrued royalties Accrued Royalties, Current International International [Member] International Equity Components Equity Components [Axis] Related Party Related Party [Member] Cash paid, net for income taxes Income Tax Paid, after Refund Received Potential contingent payments (percent) Business Combination, Contingent Consideration, Liability, Percentage Business Combination, Contingent Consideration, Liability, Percentage Common Class A Class A Common Stock Common Class A [Member] Entity Interactive Data Current Entity Interactive Data Current Variable Rate [Axis] Variable Rate [Axis] Current portion of financing lease liabilities Finance Lease, Liability, Current Less: Net income attributable to non-controlling interests Less: Net income attributable to non-controlling interests Net Income (Loss) Attributable to Noncontrolling Interest Accounts payable and accrued expenses Total accounts payable and accrued expenses Accounts Payable and Accrued Liabilities, Current Entity Small Business Entity Small Business Comprehensive (loss) income attributable to Amneal Pharmaceuticals, Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Property, Plant, and Equipment [Line Items] Property, Plant, and Equipment [Line Items] Weighted-Average Useful Life (in years) Intangible Asset, Finite-Lived, Acquired, Weighted-Average Amortization Period Government Investigations Government investigations Government Investigations [Member] Government Investigations Zambon Biotech S.A. License Agreement with Zambon Biotech [Member] License Agreement with Zambon Biotech MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Other assets Total other assets Other Assets, Noncurrent Proceeds from alliance party Proceeds from Alliance and Collaboration Agreements Proceeds from Alliance and Collaboration Agreements Document Type Document Type Acquisition of Kashiv, net of cash and restricted cash acquired Payments to Acquire Businesses, Net of Cash Acquired Litigation settlement, product supply amount Litigation Settlement, Product Supply Amount Litigation Settlement, Product Supply Amount Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Loss on refinancing Loss on refinancing Gain (Loss) on Extinguishment of Debt Charges for property losses and associated expenses Charges For Property Losses And Associated Expenses Charges For Property Losses And Associated Expenses Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] AvPROP, LLC - operating lease Av Prop L L C [Member] AvProp, LLC. Intangible asset impairment charges Intangible Asset, Excluding Goodwill, Impairment Loss Foreign currency translation adjustments arising during the period Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Subsequent Event [Line Items] Subsequent Event [Line Items] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Local Phone Number Local Phone Number Deferred income Contract with Customer, Liability, Noncurrent 2025 Revolving Credit Facility 2025 Revolving Credit Facility [Member] 2025 Revolving Credit Facility Contingent payments Payment for Contingent Consideration Liability, Operating Activities Inventory and cost of goods sold Inventory and Cost of Goods Sold [Member] Inventory and Cost of Goods Sold Income (loss) before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Commitments and contingencies (Notes 4, 18 and 20) Commitments and Contingencies Schedule of Other Long-Term Liabilities Other Noncurrent Liabilities [Table Text Block] Total property, plant, and equipment Property, Plant, and Equipment, before Accumulated Depreciation, Depletion, and Amortization Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] 2030 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Four Machinery and equipment Machinery and Equipment [Member] Liability to be settled with cash Estimated Litigation Liability, to be Settled with Cash Estimated Litigation Liability, to be Settled with Cash Executive Category: Executive Category [Axis] Liabilities for legal matters - long term Civil prescription opioid litigation (Liabilities for legal matters - long term) Estimated Litigation Liability, Noncurrent Intas Pharmaceuticals Limited License Agreement Intas Pharmaceuticals Limited License Agreement [Member] Intas Pharmaceuticals Limited License Agreement Counterparty Name Counterparty Name [Axis] Liabilities and Stockholders’ Equity (Deficiency) Liabilities and Equity [Abstract] Inventories Total inventories Inventory, Net Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Litigation Settlement, Option Two Litigation Settlement, Option Two [Member] Litigation Settlement, Option Two Other Other Selling, General and Administrative Expense Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Reclassification of cash flow hedge to earnings, net of tax of $0 Reclassification of cash flow hedge to earnings, net of tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax PEO Name PEO Name Leasehold improvements Leasehold Improvements [Member] Unrealized (loss) gain on cash flow hedge, net of tax Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] License supply agreement, potential future milestone payments License Supply Agreement, Potential Future Milestone Payments License Supply Agreement, Potential Future Milestone Payments Property, Plant and Equipment, Type Long-Lived Asset, Class [Axis] Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Related party receivables Increase (Decrease) in Due from Related Parties Entity Tax Identification Number Entity Tax Identification Number Measurement input Business Combination, Contingent Consideration, Liability, Measurement Input Unrealized gain (loss) on cash flow hedge, net of tax of $0 Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax Schedule of Acquired Intangible Assets Business Combination, Intangible Asset, Acquired, Finite-Lived and Indefinite-Lived [Table Text Block] Accrued other Other Accrued Liabilities, Current Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Base Rate Base Rate [Member] Business Interruption Loss [Axis] Business Interruption Loss [Axis] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Addition due to the Kashiv Acquisition Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Restricted cash Restricted cash - end of period Restricted Cash and Cash Equivalent, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Debt Instrument Debt Instrument [Axis] Subsequent Event [Table] Subsequent Event [Table] Other long-term liabilities Business Combination, Recognized Liability Assumed, Other Liability, Noncurrent Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Employee compensation and benefits Labor and Related Expense Payments for repurchase of redeemable noncontrolling interest Payments for Repurchase of Redeemable Noncontrolling Interest Amounts of transaction with related party Related Party Transaction, Amounts of Transaction Schedule of Fair Values of Derivative Instruments in Consolidated Balance Sheets Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block] Basic (in dollars per share) Earnings Per Share, Basic Measurement Input Type [Axis] Measurement Input Type [Axis] Accretion of redeemable non-controlling interests Accretion to redemption value Temporary Equity, Accretion to Redemption Value Total current assets Assets, Current Lease terms relative to market Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Lease Terms Relative To Market Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Lease Terms Relative To Market Related party payables Increase (Decrease) in Due to Related Parties Insider Trading Arrangements [Line Items] Long-term debt, net Total long-term debt, net Long-Term Debt, Excluding Current Maturities Payments of deferred financing and refinancing costs Payments of Financing Costs Receivables Trade accounts receivable, net Related party receivables - short term Accounts Receivable, after Allowance for Credit Loss, Current Kashiv Rupee Term Loan Facility Kashiv Rupee Term Loan Facility [Member] Kashiv Rupee Term Loan Facility Oral solid Oral Solid [Member] Oral Solid Taxes on other Other Comprehensive Income, Other, Tax Other Comprehensive Income, Other, Tax Subtotal dosage forms Subtotal Dosage Forms [Member] Subtotal Dosage Forms Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Redeemable non-controlling interests Redeemable Non-Controlling Interests, beginning balance Redeemable Non-Controlling Interests, ending balance Temporary Equity, Including Noncontrolling Interest Development and commercialization agreement - Omalizumab Research And Development, Development And Commercialization Agreement - Omalizumab [Member] Research And Development, Development And Commercialization Agreement - Omalizumab Contingent consideration Fair value Business Combination, Contingent Consideration, Liability Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Cover [Abstract] Cover [Abstract] Acquisition of product rights and licenses Noncash or Part Noncash Acquisition, Intangible Assets Acquired Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Concentration risk (as a percent) Concentration Risk, Percentage Equity Awards Adjustments Equity Awards Adjustments [Member] Alliance and Collaboration Collaborative Arrangement Disclosure [Text Block] Cash Discount Allowances Cash Discount Allowances [Member] Cash Discount Allowances [Member] Taxes on other Stockholders' Equity, Other, Tax Stockholders' Equity, Other, Tax Schedule of Trade Accounts Receivable, Net Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Other income, net Other Nonoperating Income (Expense) 2031 Intangible Asset, Finite-Lived, Estimated Amortization Expense, Year Five Schedule of Accounts Payable and Accrued Expenses Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Stockholders’ Equity (Deficiency) Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Contingent liabilities, percentage Business Combination, Contingent Liabilities, Percentage Business Combination, Contingent Liabilities, Percentage Litigation settlement on product Litigation Settlement, Product Settlement Litigation Settlement, Product Settlement Hedging Designation Hedging Designation [Domain] Class of Stock Class of Stock [Domain] Litigation Settlement, Option [Domain] Litigation Settlement, Option [Domain] Litigation Settlement, Option [Domain] Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] IPR&D In Process Research and Development [Member] Tranche One Regulatory Milestones, Tranche One [Member] Regulatory Milestones, Tranche One Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Income Taxes Income Tax Disclosure [Text Block] Accounts payable Accounts Payable, Current Equipment deposits Equipment Deposits, Noncurrent Equipment Deposits, Noncurrent Other operating charges and credits, net Other Noncash Income (Expense) Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Biosimilar Biosimilar [Member] Biosimilar Total purchase price Preliminary fair value of consideration transferred Business Combination, Consideration Transferred Entity Filer Category Entity Filer Category Increase (decrease) in tax receivable agreement liability Increase in Tax Receivable Agreement Liability - Members Tax Receivable Agreement T R A Liability [Member] Increase in Tax Receivable Agreement Liability - Members Tax Receivable Agreement T R A Liability Repayment of certain Kashiv debt obligations Business Combination, Consideration Transferred, Repayment Of Debt Obligations Business Combination, Consideration Transferred, Repayment Of Debt Obligations SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items] Concentration Risk Benchmark Concentration Risk Benchmark [Domain] Schedule of Assets And Liabilities Lessee Assets And Liabilities Lessee [Table Text Block] Assets And Liabilities, Lessee [Table Text Block] AvKARE AvKARE Segment [Member] AvKARE segment. Ownership interest (percent) Percentage Of Ownership Interest Percentage of ownership interest. Schedule of Stock by Class [Table] Stock, Class of Stock [Table] Net income Net income Net income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Current assets: Assets, Current [Abstract] Generic development supply agreement - development activity deferred income Accounts Payable And Accrued Expenses - Generic Development Supply Agreement - Development Activity Deferred Income [Member] Accounts Payable And Accrued Expenses - Generic Development Supply Agreement - Development Activity Deferred Income Net revenue Business Combination, Pro Forma Information, Pro Forma Revenue Senior Notes Senior Notes [Member] Entity Address, Address Line One Entity Address, Address Line One Sutaria Family Realty, LLC - operating lease Sutaria Family Realty, LLC [Member] Sutaria Family Realty, LLC Provision for (benefit from) income taxes Provision for (benefit from) income taxes Income Tax Expense (Benefit) Loss Contingency, Nature Loss Contingency, Nature [Domain] Number of states, filed civil lawsuit Loss Contingency Civil Lawsuit Filed Number Of States Loss Contingency, Civil Lawsuit Filed, Number Of States Number of products launched Number Of Products Launched Number Of Products Launched 2027 Litigation Settlement, To Be Paid, Year One Litigation Settlement, To Be Paid, Year One Statement [Table] Statement [Table] Proceeds from exercise of stock options Proceeds from Stock Options Exercised Unrealized foreign currency loss (gain) Unrealized Gain (Loss), Foreign Currency Transaction, before Tax Loss contingency, damages sought, value Loss Contingency, Damages Sought, Value Tax receivable agreement liability - short term Income Tax, Liabilities Under Tax Receivable Agreement, Current Income Tax, Liabilities Under Tax Receivable Agreement, Current Denosumab Biosimilar Licensing and Supply Agreement Denosumab Biosimilar Licensing and Supply Agreement [Member] Denosumab Biosimilar Licensing and Supply Agreement Prepaid expenses and other current assets Business Combination, Recognized Asset Acquired, Prepaid Expense and Other Asset, Current Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract]